Study questions unnecessary antifungal use in intensive care
NCT ID NCT03774316
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether it's safe to reduce or stop antifungal drugs early in immunocompromised ICU patients suspected of having a fungal infection. Researchers tracked 275 patients across 14 ICUs to see how often doctors de-escalated treatment and what factors influenced that decision. The goal is to learn how to avoid unnecessary side effects and drug resistance without harming patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors safely reduce unnecessary antifungal use in ICU patients, lowering side effects and costs.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks at patterns and safety, so it won't prove a new therapy works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Lille
Lille, 59000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may predict transfusion needs to shield ICU patients from organ failure
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- A simple blood test trend may flag ICU patients at risk
- Could a simple CT scan reveal which ICU cancer patients are at highest risk?
- A gentle touch from family may calm the ICU storm
- Can a quick PCR test speed up lifesaving fungal infection diagnosis?